Targeting Stat3 Potentiates Cdk4/6 Inhibitors Therapy in Hnscc DOI
Dong Lin,

Haoyang Sun,

Chao Liu

et al.

Published: Jan. 1, 2024

Download This Paper Open PDF in Browser Add to My Library Share: Permalink Using these links will ensure access this page indefinitely Copy URL DOI

Language: Английский

Untangling the Role of MYC in Sarcomas and Its Potential as a Promising Therapeutic Target DOI Open Access

Fabio Sias,

Stefano Zoroddu, Rossana Migheli

et al.

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(5), P. 1973 - 1973

Published: Feb. 25, 2025

MYC plays a pivotal role in the biology of various sarcoma subtypes, acting as key regulator tumor growth, proliferation, and metabolic reprogramming. This oncogene is frequently dysregulated across different sarcomas, where its expression closely intertwined with molecular features unique to each subtype. interacts critical pathways such cell cycle regulation, apoptosis, angiogenesis, amplifying aggressiveness resistance standard therapies. Furthermore, influences microenvironment by modulating cell-extracellular matrix interactions immune evasion mechanisms, further complicating therapeutic management. Despite well-established centrality pathogenesis, targeting directly remains challenging due "undruggable" protein structure. However, emerging strategies, including indirect inhibition via epigenetic modulators, transcriptional machinery disruptors, pathway inhibitors, offer new hope for treatment. review underscores importance understanding intricate roles subtypes guide development effective targeted Given MYC's central tumorigenesis progression, innovative approaches aiming at could transform landscape patients, providing much-needed avenue overcome improve clinical outcomes.

Language: Английский

Citations

0
UPS and Kinases—Gatekeepers of the G1/S Transition DOI
Srija Roy, Gouranga Saha, Mrinal K. Ghosh

et al.

BioFactors, Journal Year: 2025, Volume and Issue: 51(3)

Published: April 30, 2025

The G1/S transition is a highly regulated and pivotal checkpoint in the cell cycle, where decides whether to commit DNA replication subsequent division or enter non-dividing state. This serves as critical control point for preventing uncontrolled proliferation maintaining genomic stability. major driving force underlying sequential activation of Cyclin-dependent kinases (CDKs), which by coordinated binding Cyclin partners, well phosphorylation ubiquitin-mediated degradation both partners kinase inhibitors (CKIs). Various E3 ligase families govern timely these regulatory proteins, with their activity intricately controlled events. coordination enables cells efficiently translate environmental cues molecular signaling inputs determine fate. We explore evolution three distinct models describing transition, highlighting how traditional linear model being challenged recent paradigm shifts conflicting findings. These advances reveal emerging complexity unresolved questions field, particularly regarding latest insights into ubiquitination-dependent integrate contemporary transition.

Language: Английский

Citations

0
Cell cycle regulation by the ribotoxic stress response DOI
Connor McKenney, Sergi Regot

Trends in Cell Biology, Journal Year: 2025, Volume and Issue: unknown

Published: May 1, 2025

Language: Английский

Citations

0
The involvement of cyclin-dependent kinase 7 (CDK7) and 9 (CDK9) in coordinating transcription and cell cycle checkpoint regulation DOI Creative Commons

Cheng‐Fan Lee,

Kenneth J. Pienta, Sarah R. Amend

et al.

Cell Cycle, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 13

Published: April 14, 2025

Cells regulate the expression of cell cycle-related genes, including cyclins essential for mitosis, through transcriptional activity positive transcription elongation factor b (P-TEFb), a complex comprising CDK9, cyclin T, and factors. P-TEFb cooperates with CDK7 to activate RNA polymerase. In response DNA stress, cycle shifts from mitosis repair, triggering arrest activation repair genes. This tight coordination between transcription, progression, stress is crucial maintaining cellular integrity. Cyclin-dependent kinases CDK9 are central both regulation. functions as CDK-activating kinase (CAK), activating other CDKs, while acts critical integrator signals machinery. review elucidates mechanisms by which mitotic process checkpoints, emphasizing their roles in balancing growth, homeostasis, control.

Language: Английский

Citations

0
Breaking through therapeutic barriers: Insights into CDK4/6 inhibition resistance in hormone receptor-positive metastatic breast Cancer DOI
Yang Zheng, Zeyuan Zhang,

Dan Li

et al.

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, Journal Year: 2024, Volume and Issue: 1879(5), P. 189174 - 189174

Published: Aug. 30, 2024

Language: Английский

Citations

2
Investigating Heterogeneous Cell-Cycle Progression Using Single-Cell Imaging Approaches DOI
Hee Won Yang

Methods in molecular biology, Journal Year: 2024, Volume and Issue: unknown, P. 263 - 273

Published: Jan. 1, 2024

Language: Английский

Citations

0
Clinical Impact of C-myc Oncogenic Diversity on Solid and Lymphoid Malignancies DOI

Sotirios Papouliakos,

Aristeidis Chrysovergis, Vasileios Papanikolaou

et al.

MAEDICA – a Journal of Clinical Medicine, Journal Year: 2024, Volume and Issue: 19(2)

Published: June 15, 2024

Onset and progression of malignant tumors is a multistep process including variety gross chromosomal specific genes' deregulation. Among oncogenes that are frequently altered in solid also hematological malignancies, the C-myc (gene locus: 8q24.21) plays pivotal role. proto-oncogene encoding for nuclear phosphoprotein implicated cell cycle progression, apoptosis cellular differentiation transformation.

Language: Английский

Citations

0
Therapeutic benefits of maintaining CDK4/6 inhibitors and incorporating CDK2 inhibitors beyond progression in breast cancer DOI Creative Commons

Jessica Armand,

Sungsoo Kim, Jae Hyun Kim

et al.

bioRxiv (Cold Spring Harbor Laboratory), Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 15, 2024

The combination of CDK4/6 inhibitors (CDK4/6i) and endocrine therapy has revolutionized treatment for hormone receptor-positive (HR+) metastatic breast cancer. However, the emergence resistance in most patients often leads to discontinuation with no consensus on effective second-line therapies. therapeutic benefits maintaining CDK4/6i or incorporating CDK2 (CDK2i) after disease progression remain unclear. Here, we demonstrate that sustained therapy, either alone combined CDK2i, significantly suppresses growth drug-resistant HR

Language: Английский

Citations

0
The significance of RB1 in multiple myeloma DOI Creative Commons
Yiwen Wang, Rui Yang, Rui Liu

et al.

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: Nov. 27, 2024

The treatment of multiple myeloma (MM) has significantly advanced; however, the underlying genetic mechanisms remain elusive. Clonal events and alterations are recognized as pivotal in pathogenesis MM. It is now understood that a multitude gene mutations, including those affecting RAS,

Language: Английский

Citations

0
Role of Apoptosis in Cancer: War of the Worlds, Therapeutic Targets and Strategies DOI

Aiindrila Dhara,

Ramandeep Kaur,

Ranajoy Chattopadhyay

et al.

Published: Jan. 1, 2024

Language: Английский

Citations

0